By Rhiannon Riches
ZEISS has announced the release of SITA Faster strategy on Humphrey Field Analyzer 3 (HFA3) to improve workflow efficiencies, diagnostic performance and patient experience.
Renato Antolovich, Product Manager – Retina & Glaucoma, in ZEISS’s Medical Technology Business Group said the SITA Faster strategy will improve testing times.
‘Visual field testing is often a significant bottleneck in a practice with long testing times challenging the patient’s satisfaction, test reliability and clinical workflow,’ Mr Antolovich said.
The company said many practitioners have experienced improved testing time by up to 50 per cent with the new SITA Faster strategy on the HFA3, with SITA Faster 24-2 test strategy performing clinically equivalent and reproducible tests for normal and glaucomatous eyes in only two to three minutes.1,2
‘These sought after efficiencies are essential to handle the ever-increasing glaucoma patient volume while maintaining the highest level of care and clinical confidence from your perimeter,’ Mr Antolovich said.
‘The possibility of intermixing all SITA strategies for Guided Progression Analysis reports further facilitates the seamless transition and immediate adoption of the newest SITA Faster strategy in clinics that wish to increase patient throughput and provide a more positive diagnostic experience to their patients,’ Mr Antolovich said.
Optometrist Michael Targett uses the ZEISS HFA3 in his Brighton Eyewear practice.
‘I’ve had my HFA3 for 12 months, and I was already pleased with the faster testing times and data rich reports but the upgrade to SITA Faster has been another step up.
‘The new strategy means a full threshold test only takes two to three minutes, and that means more reliable results, better patient compliance, and a more efficient workflow for me,’ he said.
1. Patella, VM et al. Clinical Evaluation of a New Perimetric Testing Algorithm, SITA Faster. Paper presented at: The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2018 May 3; Honolulu, HI. Abstract nr 6031
2. Based on data from internal validation trials